ArticleBritish journal of clinical pharmacology2018
Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
Article in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients.British journal of clinical pharmacology · 2023Trial
- Trial
- Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer.Clinical pharmacokinetics · 2026Article
- Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.British journal of clinical pharmacology · 2026Article
- Personalized intensification of treatment for hormone-sensitive prostate cancer.Nature reviews. Clinical oncology · 2026Review
- Managing Drug Interactions with Enzalutamide in Patients with Prostate Cancer: A Podcast.Drug safety · 2026Article
- Prevalence and clinical significance of potential drug-drug interactions of antimicrobials in Intensive Care Unit patients: a retrospective study.BMC pharmacology & toxicology · 2025Article
- Concomitant Administration of Psychotropic and Prostate Cancer Drugs: A Pharmacoepidemiologic Study Using Drug-Drug Interaction Databases.Biomedicines · 2024Article
- Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy.Drug safety · 2024Review
- Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents.Journal of cancer research and clinical oncology · 2023Observational
- Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.Clinical pharmacokinetics · 2023Article
- Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review.Therapeutic advances in medical oncology · 2023Review
- New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial.Journal of clinical medicine · 2022Article
- Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends.Clinical drug investigation · 2022Review
- Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.Clinical and translational science · 2022Article
- Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer.Prostate international · 2022Article
- Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.Prostate cancer and prostatic diseases · 2021Review
- Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists.Current oncology (Toronto, Ont.) · 2021Review
- Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Prevalence of potential drug-drug interactions in outpatients of a general hospital in China: a retrospective investigation.International journal of clinical pharmacy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMetastatic castration-resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore at increased risk of complications due to drug-drug interactions (DDIs). We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide.
methodsWe conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting. Potential DDIs were analysed using two international drug interaction compendia: Lexicomp
resultsA total of 105 records were evaluated for potential DDIs with enzalutamide. Of 205 different co-medications, 56 were flagged by at least one of the three compendia: Lexicomp, Micromedex and the Dutch drug database flagged for potential DDIs in 85%, 54% and 32%, respectively. Eighty-five per cent of DDIs were classified as major. The median number of co-medications per patient was 11 (range 1-26). The median (range) number of interactions per patient was 4 (0-10), 1 (0-5) and 0 (0-2) for Lexicomp, Micromedex and the Dutch drug database, respectively. In 23% and 45% of all patients, a potential DDI was found with PPIs and CNS depressants, respectively.
conclusionsA high prevalence of potential DDIs was found. The inclusion and grading of potential DDIs was highly variable between the three drug interaction compendia. Physicians, nurses and pharmacists should be aware of this potential problem, which might require intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.